Exclusive Policy planning in process to boost domestic production

  • News
  • October 17, 2017

India is making a great move to revive India’s active pharmaceutical ingredient (API) and bulk drug market because today 80% of India’s bulk drug imports come from China because of its low API prices.

In finished generic drugs,  India is a leader in pharma industry but Indian pharma manufacturers importing costly drug APIs from China as the Indian government is not in their support and they will not get any incentives from the government to produce APIs.

Now, Commerce and finance ministry actively mulling over to draft an exclusive policy to develop bulk drug parks, medical device parks and formulation parks as this will help the government to boost domestic API production and serves as the best alternative to costly imports from China.

In the financial year 2016, India got APIs worth Rs.13,853 crore from China or 65.3% of the total Rs.21,217 crore including ingredients for essential antibiotics. With this new policy, India can remove the dependency on China for raw products.

APIs also known as bulk drugs, are the active raw materials used in a medicine that gives it the therapeutic effect.  A major point to be considered for Indian Pharma Industry is that bulk drugs which can be indigenously manufactured and imported at peak customs duty.

China, because of its large-scale manufacturing capabilities becomes a dominant player for API production and low prices attract users to buy their APIs. So to secure India drug security as a whole, its a time to set up bulk drug parks, medical device parks, and formulation parks.

Maharashtra Government took a step ahead to fulfilling the mandate, met drug manufacturers to explore the potential of Special Economic Zone (SEZ) in and around Multi-modal International Cargo Hub and Airport (MIHAN) at Nagpur. It is developed as a pharma hub and will further incentivize local drug manufacturers thus giving impetus to the ‘Make in India’ campaign. MIHAN project aims to exploit the central location of Nagpur and convert the Dr. Babasaheb Ambedkar International Airport into a major cargo hub with integrated road and rail connectivity.

The center plan is in discussions for setting up the medical devices park in Gujarat and in the last year, the Andhra Pradesh government had laid the foundation stone for India’s first government-funded medical devices park Andhra MedMedTech Zone (AMTZ) in Visakhapatnam.

  • Related Posts

    ‘A Knight in Shining Armor’ packed a punch in FOGSI for Gender Equality

    New Delhi: There was no fog in sight; FOGSI was shining as never before, thanks to the leadership of its outgoing president Dr Hrishikesh Pai. The over 40, 000 strong…

    • News
    • December 16, 2023
    • 24 views
    Women are on Trajectory to make Presence Felt in Healthcare India

    New Delhi: It could be advantage patients in times to come as women as workforce are increasing in healthcare domain of India. It is given that women power blended with…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Regular Supplier Of Stents Ignored By Doctors Due To Low Commission; Company Supplying Despite Crores Of Dues

    Regular Supplier Of Stents Ignored By Doctors Due To Low Commission; Company Supplying Despite Crores Of Dues

    ACB Gujarat Nabs Female Drug Inspector In A Bribe Case

    ACB Gujarat Nabs Female Drug Inspector In A Bribe Case

    Netherlands: Health Secy Visits Bilthoven Biologicals, Discusses Collaboration On Production Of Oral Polio Vaccine

    Netherlands: Health Secy Visits Bilthoven Biologicals, Discusses Collaboration On Production Of Oral Polio Vaccine

    India Lifts Safeguard Measures On Isopropyl Alcohol Imports

    India Lifts Safeguard Measures On Isopropyl Alcohol Imports

    Punjab And Haryana HC Notice To Centre On Petition Against Misuse Of Oxytocin

    Punjab And Haryana HC Notice To Centre On Petition Against Misuse Of Oxytocin

    Nepal Drugs Regulator To Conduct On-Site Testing Of Medicines

    Nepal Drugs Regulator To Conduct On-Site Testing Of Medicines